Showing results (31-40 of 433) with videos related to
Sort By:
Pageof 44
Journal of the American College of Cardiology|August 1, 2015
10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome: The British Heart Foundation RITA-3 Randomized TrialRobert A Henderson, Christopher Jarvis, Tim Clayton, et al.European Heart Journal|December 10, 2024
Type 2 myocardial infarction: challenges in diagnosis and treatmentAndrew R Chapman, Caelan Taggart, Jasper Boeddinghaus, et al.European Heart Journal|September 26, 2009
Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91,246 ambulant patients in 27 European countriesKeith A A Fox, Jean-Pierre Després, Alain-Jean Richard, et al.Expert Review of Cardiovascular Therapy|January 3, 2014
Is myocardial ischemia really bad for you?Marc R Dweck, Iqbal Toor, Andrew D Flapan, et al.Journal of the American College of Cardiology|September 13, 2002
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapyFraser N Witherow, Pamela Dawson, Christopher A Ludlam, et al.Circulation|May 8, 2002
Increased platelet binding to circulating monocytes in acute coronary syndromesJaydeep Sarma, Caterina A Laan, Shirjel Alam, et al.Circulation|May 22, 2020
The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular DiseaseJan Steffel, John W Eikelboom, Sonia S Anand, et al.Circulation|April 30, 2019
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery DiseasePaul A Gurbel, Keith A A Fox, Udaya S Tantry, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|April 15, 2003
Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humansStanley Chia, Motaz Qadan, Richard Newton, et al.Expert Opinion on Investigational Drugs|May 22, 2008
Rivaroxaban, an oral direct factor Xa inhibitorJonathan P Piccini, Manesh R Patel, Kenneth W Mahaffey, et al.Pageof 44